A Phase 2 interventional study of Masitinib Mesylate and Placebo in Covid19, SARS-CoV2 Infection and Coronavirus Disease 2019, sponsored by AB Science. Status unknown at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.
Sponsored by AB Science · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in COVID-19 with a site in Russian Federation — 4 open to participants now, 9 under way, 1 of them phase 3. COVID-19 · Russian Federation.
Among the 144 studies in COVID-19 with a site in Russian Federation, this one is the 80th largest by planned enrollment of the 105 interventional ones that give a count, is one of 38 that started in 2021, is one of 19 in phase 2, and was the 94th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →4 of the 144 studies in COVID-19 with a site in Russian Federation are open now. Recruiting first, the newest first:
Masaryk University · Sites in Russian Federation, United States, Canada and 11 more countries
Ages 18+
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Sites in Russian Federation
Ages 18+ · Healthy volunteers
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 18–80
Valenta Pharm JSC · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 41 · Phase 3 51 · Phase 4 6
First in 2018; this study’s year is marked. 38 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is below the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 198 across the 105 interventional studies, 220 across the 39 observational. Of the 107 that completed or were terminated, 27 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 144 have an industry lead sponsor. The 10 most frequent:
AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AB Science has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies in COVID-19 with a site in Russian Federation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04522076National Research Center for Preventive MedicineProspective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 144 studies in COVID-19 with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
The primary objective is to evaluate the virologic efficacy of masitinib plus Best Supportive Care (BSC), with respect to placebo plus BSC in reducing viral shedding of SARS-CoV-2 in patients with symptomatic mild to moderate COVID-19.
Patients will be randomized into one of the following treatment groups (all patients will receive BSC):
Regarding Best Supportive Care, for patients with a score of 2 and 3 (ambulatory) on the 10-score WHO clinical progression scale, Best Supportive Care is best available therapy in the country at the choice of the investigator excluding any antiviral treatment whether indirect (Ribavirin, Hydroxychloroquine or Chloroquine) or direct (anti-polymerase or antiprotease, including lopinavir/ritonavir fixed dose combination), other investigational treatments for SARS-CoV-2, plasma from a person who recovered from COVID-19, monoclonal antibody therapies and vaccine. For patients with a score of 4 and 5 (hospitalized) on the 10-score WHO clinical progression scale, Best Supportive Care is dexamethasone.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo (all patients will receive Best Supportive Care)
Drug: Masitinib Mesylate
Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus corresponding placebo (all patients will receive Best Supportive Care)
Drug: Masitinib Mesylate
Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day for 6 days versus corresponding placebo (all patients will receive Best Supportive Care)
Drug: Masitinib Mesylate
Placebo arms associated with the three Experimental arms (all patients will receive Best Supportive Care) which will be pooled for analysis
Drug: Placebo
3CL-protease inhibitor
Also known as: Masitinib, AB1010
Placebo
SARS-Cov-2 Viral Load at Day 10
Time-weighted average change from baseline in viral shedding
Time frame: Baseline to Day 10
SARS-Cov-2 Viral Load to post-baseline study days
Time-weighted average change from baseline in viral shedding
Time frame: Baseline up to Day 28
Time to negative RT-qPCR result
Time to negative RT-qPCR result in all tested samples with no subsequent positive RT-qPCR in any tested samples
Time frame: Baseline up to Day 28
Plan to share: No — Masitinib is under clinical investigation and has not yet been approved in any sought-after indication by any health authority worldwide. As such, there is no plan for data-sharing at this point in time.
Started Nov 2021 (actual). Primary completion is estimated for Dec 2023, 25 months after the start.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 25 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Masitinib